AstraZeneca announces Euan Ashley appointed director at DexCom

Rhea-AI Filing Summary

AstraZeneca PLC announced that Non-Executive Director Euan Ashley has been appointed a director of DexCom, Inc., effective 24 October 2025.

This routine governance disclosure was made pursuant to Listing Rule 6.4.9 (2). The notice was signed by Company Secretary Matthew Bowden on 28 October 2025.

Form 6-K: How Foreign Companies Report to the SEC →

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Director Declaration

28 October 2025

Director Declaration

AstraZeneca PLC (the Company) today announced that Euan Ashley, Non-Executive Director of the Company, has been appointed a director of DexCom, Inc. with effect from 24 October 2025.

This announcement is made pursuant to Listing Rule 6.4.9 (2).

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 October 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What did AstraZeneca (AZN) disclose in this Form 6-K?

AstraZeneca reported that Non-Executive Director Euan Ashley was appointed a director of DexCom, Inc. effective 24 October 2025.

Who is the AstraZeneca board member mentioned and what is the new role?

Non-Executive Director Euan Ashley has been appointed a director of DexCom, Inc..

When does Euan Ashley’s DexCom appointment take effect?

The appointment is effective 24 October 2025.

Under which rule was this announcement made?

The disclosure was made pursuant to Listing Rule 6.4.9 (2).

Who signed the notice for AstraZeneca (AZN)?

The notice was signed by Matthew Bowden, Company Secretary, on 28 October 2025.

What filing format did AstraZeneca use for this update?

AstraZeneca furnished a Form 6-K report of foreign issuer.